Reported 2 days ago
This article evaluates Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), which has been ranked as one of the worst blue-chip stocks to buy, reflecting a 26.2% decline year-to-date. Despite challenges, analysts maintain a positive outlook, highlighting the company's potential for long-term growth driven by diverse revenue streams and an exciting pipeline of new drug candidates. With the backdrop of market rotations favoring value stocks, investors are encouraged to consider various factors, including the company's innovations and strategic responses to market changes.
Source: YAHOO